Showing results (111-120 of 164) with videos related to
Sort By:
Pageof 17
British Journal of Cancer|January 24, 2018
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumoursJeffrey R Infante, Ronald L Korn, Lee S Rosen, et al.British Journal of Cancer|September 27, 2017
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumoursJeffrey R Infante, Ronald L Korn, Lee S Rosen, et al.The Oncologist|June 9, 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRASChristopher H Lieu, Manuel Hidalgo, Jordan D Berlin, et al.Investigational New Drugs|August 7, 2019
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanomaShahneen Sandhu, Catriona M McNeil, Patricia LoRusso, et al.Cancer Research Communications|June 30, 2023
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal CancerMichael Cecchini, Janie Y Zhang, Wei Wei, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2008
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapyStephen Johnston, Maureen Trudeau, Bella Kaufman, et al.British Journal of Cancer|May 17, 2025
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa studyTimothy A Yap, Patricia LoRusso, Rowan E Miller, et al.British Journal of Cancer|October 27, 2018
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation studyPamela Munster, Ian E Krop, Patricia LoRusso, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2023
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or LymphomasMrinal M Gounder, Todd M Bauer, Gary K Schwartz, et al.JNCI Cancer Spectrum|July 19, 2023
Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operationsThomas J George, Tara L Lin, Tricia Adrales Bentz, et al.Pageof 17